ADRB2 and cancer: Retrospective analysis on cancer patients undergoing β-blocker treatment (βAR antagonists) on its own [44,45] or in combination with immunotherapy [46] has suggested a clinical impact, but obviously prospective clinical trials are needed to support that notion.